Back to top
more

Masimo (MASI)

(Delayed Data from NSDQ)

$143.49 USD

143.49
737,855

+3.55 (2.54%)

Updated Oct 9, 2024 04:00 PM ET

After-Market: $143.53 +0.04 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (94 out of 252)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Masimo (MASI) Beats on Q3 Earnings, 2018 Guidance Impressive

Masimo (MASI) gains from strong Product revenues in Q3; raises 2018 outlook.

Masimo (MASI) Beats Q3 Earnings and Revenue Estimates

Masimo (MASI) delivered earnings and revenue surprises of 4.41% and 2.06%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Medical Product Stock Q3 Earnings on Oct 31: BAX, MASI & More

Long-term growth prospects of the Medical Products industry looks promising despite certain short-term political conundrums.

Zimmer Biomet (ZBH) Q3 Earnings Top Estimates, Margins Down

We are encouraged by Zimmer Biomet's (ZBH) consistent effort in product renovation through research and development.

Omnicell (OMCL) Earnings & Revenues Beat Estimates in Q3

Omnicell's (OMCL) third-quarter 2018 performance impresses with year-over-year growth in earnings and revenues.

ResMed (RMD) Q1 Earnings & Sales Beat on Overall Growth

ResMed (RMD) sees solid contributions from domestic and international businesses in Q1.

Will Advance Medical Buyout Aid Teladoc (TDOC) Q3 Earnings?

Teladoc (TDOC) is expected to chip in with a solid top-line contribution from its acquisition of Advance Medical in Q3.

Can CAG Growth Steadily Drive IDEXX (IDXX) in Q3 Earnings?

IDEXX's (IDXX) efforts to enhance its commercial capabilities in the United States to maintain a recurring revenue rise at CAG Diagnostics are encouraging.

Will Product Revenues Drive Masimo's (MASI) Q3 Earnings?

Masimo's (MASI) Product revenues likely to drive Q3; guidance for 2018 raised.

Align Technology (ALGN) Beats on Earnings and Revenues in Q3

Align Technology (ALGN) gains on solid contributions from Clear Aligner as well as Scanner and Service segments in Q3.

Will Robust ICL Sales Aid STAAR Surgical (STAA) Q3 Earnings?

STAAR Surgical (STAA) is expected to pitch in a solid top-line contribution with its Implantable Collamer Lens (ICL) consisting of the EVO Visian ICL product line.

Will Amedisys' (AMED) Q3 Earnings Reflect Overall Gain?

Amedisys' (AMED) Q3 is anticipated to benefit from a strong uptick across all its three business lines consisting of Home Health, Hospice and Personal Care.

LabCorp (LH) Q3 Earnings Lag Estimates, Guidance Tweaked

Within LabCorp (LH) Diagnostics business the disposition of certain businesses and the implementation of the Protecting Access to Medicare Act (PAMA) dented growth.

Thermo Fisher (TMO) Beats on Q3 Earnings, Ups '18 Guidance

Thermo Fisher (TMO) raises its 2018 revenue view, banking on a solid third-quarter operational performance, partially offset by a less favorable foreign exchange.

Edwards Lifesciences (EW) Earnings Beat, Revenues Miss in Q3

Edwards Lifesciences (EW) gains from THVT strength on continued therapy adoption across all geographies in Q3.

Masimo (MASI) Q3 Earnings Preview: What to Look Out For

Masimo (MASI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Illumina (ILMN) Beats Earnings and Revenue Estimates in Q3

Illumina (ILMN) gains on strong consumables growth across its sequencing portfolio with strength in all throughput categories and microarray business in Q3.

Is Masimo (MASI) Stock Outpacing Its Medical Peers This Year?

Is (MASI) Outperforming Other Medical Stocks This Year?

Boston Scientific (BSX) Beats on Q3 Earnings, Misses Revenues

Boston Scientific (BSX) registers steady growth across all business lines and geographies in Q3.

Can Diagnostic Revenues Drive PerkinElmer (PKI) Q3 Earnings?

PerkinElmer (PKI) likely to gain from strong segmental revenues in Q3; a raised earnings guidance for 2018 is promising.

Can Medication Delivery Unit Aid Baxter's (BAX) Q3 Earnings?

Baxter (BAX) likely to gain from strong Medication Delivery revenues; guidance for 2018 raised.

Will Healthcare Arm Drive BioTelemetry's (BEAT) Q3 Earnings?

Product launches, synergies from LifeWatch acquisition and favorable payor mix are expected to have worked in favor of BioTelemetry's (BEAT) Healthcare arm in Q3.

Quest Diagnostics (DGX) Q3 Earnings Meet, Guidance Tweaked

Quest Diagnostics (DGX) gains on successful execution of its strategy of accelerating growth in Q3.

PetMed (PETS) Q2 Earnings Grow Y/Y, Reorder Sales Solid

PetMed's (PETS) reorder sales growth solid in Q2. Increased online sales buoy optimism.

What's in Store for Medpace Holdings (MEDP) in Q3 Earnings?

Medpace Holdings' (MEDP) revenue growth in Q3 to be driven by strength in oncology, cardiometabolic, antiviral and anti-infectious diseases solutions.